MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC

MAIA Biotechnology, Inc.

Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.
Estimated median OS of 17.8 months (95% CI lower bound 12.5 months), consistent with prior readout.
2 patients completed 33 cycles, suggesting extended dosing and tolerability for ateganosine.
Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.